Purpose: Dexamethasone (Dex) has long been used as a potent immunosuppressive agent in the treatment of inflammatory and autoimmune diseases, despite serious side effects. In the present study, Dex and model antigen ovalbumin (OVA) were encapsulated with poly(lacticco-glycolic acid) to deliver Dex and OVA preferentially to phagocytic cells, reducing systemic side effects of Dex. The OVA-specific immune tolerance-inducing activity of the nanoparticles (NPs) was examined. Methods: Polymeric NPs containing OVA and Dex (NP [OVA+Dex]) were prepared by the water-in-oil-in-water double emulsion solvent evaporation method. The effects of NP[OVA +Dex] on the maturation and function of immature dendritic cells (DCs) were examined in vitro. Furthermore, the OVA-specific immune tolerizing effects of NP [OVA+Dex] were confirmed in mice that were intravenously injected or orally fed with the NPs. Results: Immature DCs treated in vitro with NP[OVA+Dex] did not mature into immunogenic DCs but instead were converted into tolerogenic DCs. Furthermore, profoundly suppressed generation of OVA-specific cytotoxic T cells and production of OVA-specific IgG were observed in mice injected with NP[OVA+Dex], whereas regulatory T cells were concomitantly increased. Feeding of mice with NP[OVA+Dex] also induced OVA-specific immune tolerance. Conclusion: The present study demonstrates that oral feeding as well as intravenous injection of poly(lactic-co-glycolic acid) NPs encapsulating both antigen and Dex is a useful means of inducing antigen-specific immune tolerance, which is crucial for the treatment of autoimmune diseases.
Introduction
Dendritic cells (DCs) are the most efficient antigen presenting cells (APCs) that can prime naïve T cells. [1] [2] [3] Broadly, DCs can be classified into two functionally different populations, immunogenic DCs and tolerogenic DCs. 4 Immunogenic
DCs express high levels of co-stimulatory molecules, such as CD80 or CD86, and produce pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-12, and tumor necrosis factor (TNF)-α, enabling them to induce antigen-specific T cell priming and activation. 5, 6 In contrast, tolerogenic DCs express low levels of co-stimulatory molecules and are deficient in pro-inflammatory cytokine production and T cell stimulatory activity. Tolerogenic DCs produce immunosuppressive cytokines such as IL-10 and transforming growth factor (TGF)-β, and express higher levels of co-inhibitory molecules such as programmed deathligand 1 (PD-L1) and inducible co-stimulator ligand (ICOSL), consequently promoting the differentiation of naïve T cells into regulatory T (Treg) cells. [6] [7] [8] [9] [10] [11] [12] The therapeutic efficacy of ex vivo-generated tolerogenic DCs has been demonstrated in animal models of autoimmune diseases and graft rejection. [12] [13] [14] [15] [16] Based on the successes in small animal models, several clinical trials have been completed or are on-going in patients with autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Crohn's disease. [17] [18] [19] [20] Dexamethasone (Dex), a synthetic glucocorticoid, has 30-fold more potent immunosuppressive activity than cortisol. 21 Dex affects the differentiation, maturation, and function of many immune cells, such as T cells, macrophages, monocytes and DCs. [22] [23] [24] [25] In particular, DCs generated with Dex have the properties of tolerogenic DCs. 26, 27 Dex is used as a potent immunosuppressive and anti-inflammatory drugs to treat chronic inflammatory diseases, autoimmune diseases, and organ-graft rejection. [28] [29] [30] However, systemic administration of Dex has numerous serious side effects such as suppression of many immune cells, increased risk of infection, high blood pressure, and development of diabetes. 31, 32 Poly (D, L-lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer that is eventually hydrolyzed to lactic acids and glycolic acids in the body and removed from the body via the citric acid cycle; it is used for the generation of polymeric nanoparticles (NPs) for pharmacological uses. 33 PLGA-NPs can encapsulate biologically active compounds including hormones, antibiotics or anti-cancer drugs, or antigens such as proteins, peptides, DNA or RNA. 34 A major advantage of encapsulating pharmacological drugs with PLGA is suspended release of the drug. From an immunological point of view, PLGA-NPs containing both antigens and drugs have remarkable advantages, as they can specifically deliver the antigens and the drugs to phagocytes, such as DCs and macrophages, thus reducing the potential systemic side effects of the drugs. 34, 35 In this study, we investigated the therapeutic potential of PLGA-NPs containing both antigen and Dex. Our results show that DCs treated with PLGA-NPs containing both antigen and Dex have tolerogenic DC properties that can induce to antigen-specific as well as antigen-nonspecific immune suppression. In addition, we demonstrate that intragastric (i.g.) feeding, as well as intravenous (i.v.) injection, of PLGA-NPs containing both antigen and Dex induces antigen-specific immune tolerance in mice.
Materials and methods Animals
Female C57BL/6 and BALB/c mice (8-12 weeks old) were purchased from Kosa Bio Inc. (Seongnam, South Korea). OT-II mice were provided by Dr. Seong Kug Eo (College of Veterinary Medicine, Chonbuk National University, Iksan, South Korea). All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Chungbuk National University, Cheongju, South Korea and performed in accordance with the IACUC guidelines and regulations.
Generation of DCs from bone marrow cells
DCs were generated as previously described. 27 Briefly, bone marrow cells obtained from mouse femurs were cultured in 6-well plates (5×10 6 cells/well) in culture medium supplemented with 40 ng/mL granulocyte macrophage-colony stimulating factor and 40 ng/mL IL-4 (both from CreaGene, Seongnam, South Korea). After 3 days, the non-adherent cells were removed by gently shaking the dish and then replacing the medium. On day 4, the nonadherent cells were again removed by the same method. On day 6, half the culture medium was replaced with fresh medium. To induce maturation, DCs were exposed to 50 ng/mL interferon (IFN)-γ and 50 ng/mL tumor necrosis factor (TNF)-α (both from PeproTech Inc., Rocky Hill, NJ, USA), or treated with the indicated NPs for 48 h. The DCs were harvested by gentle pipetting on day 8.
3 min of emulsification, 11 mL of a 5% polyvinyl alcohol aqueous solution (PVA, Sigma-Aldrich) were added to the w/o emulsion to form a water-in-oil-inwater (w/o/w) double emulsion, which was homogenized for 5 min. To solidify the nanoparticles, the organic solvent was evaporated by stirring the double emulsion with 200 mL of a 0.1% PVA aqueous solution at 500 rpm for 2 h. The resulting NPs were centrifuged at 3,000 rpm for 20 min and washed twice with phosphatebuffered saline (PBS). NPs containing only OVA (NP[OVA]) were prepared by the same method without adding Dex to the PLGA solution. The NPs were prepared just before use, or frozen in aliquots at −20°C for later use.
Characterization of PLGA-NPs
The mean size and zeta-potential of NP [OVA+Dex] and NP[OVA] were measured using a particle size analyzer (ELS-Z, Otsuka, Japan). The OVA content was determined using a microbicinchoninic acid assay kit (Pierce, Rockford, IL, USA) after lysing the NP[OVA+Dex] in a lysis buffer containing 0.1% SDS and 0.1 N NaOH, as previously described. 27 
Statistical analysis
One-way ANOVA analysis and Tukey post-hoc tests were performed to compare the significance of multiple groups; p≤0.05 was considered statistically significant. .9 nm, respectively. Based on our previous experiences, we decided to prepare polymeric NPs in this range, as they are large enough to contain sufficient amounts of antigen and drug, and are the optimal size for phagocytosis by the antigen presenting cells. 38, 39 As shown in the scanning electron microphotograph, NP[OVA+Dex] had a spherical shape with a relatively homogeneous particle size Notes: The average size, polydispersity index, and zeta-potential of the NPs were measured using a particle size analyzer. The OVA content was determined using a microbicinchoninic acid assay after lysing the NPs in a lysis buffer containing 0.1% SDS and 0.1 N NaOH. The concentration of Dex was determined by high performance liquid chromatography using a YMC J'sphere ODS-H80 column (150×4.6 mm) after lysing the NPs in a 1:2 mixture of dimethyl sulfoxide and methanol. distribution ( Figure S1 ). ), CD80, and CD86 molecules, all of which are essential in antigenspecific T cell priming, compared to the control DCs ( Figure 1A and B) . The expression of PD-L1, known as an co-inhibitory molecule, was slightly reduced in DCs treated with NP [OVA+Dex] . However, the proportion of Figure 1C and D) . Phagocytosis of NPs on their own activates DC maturation and cytokine production. As shown in Figure 2 , DCs treated with NP[OVA] produce much higher amounts of pro-inflammatory cytokines, IL-1β, IL-6, IL-12 and TNF-α, than the DCs matured with cytokines. However, the production of these inflammatory cytokines was profoundly suppressed in NP[OVA+Dex]-treated DCs (Figure 2) . In contrast, NP[OVA+Dex]-treated DCs produced significantly high amount of IL-10, compared to DCs treated with NP[OVA], or matured with cytokines. There was no significant differences in TGF-β1 production.
Results

Fabrication and characterization of
The T cell stimulatory capacity of NP-treated DCs was also investigated using an MHC class II-restricted exogenous antigen presentation assay and allogeneic mixed lymphocyte reaction (MLR). In exogenous antigen presentation assays, DCs were incubated with the NPs for 2 h, washed and fixed, and then co-cultured with OVA-specific CD4 Figure 5A and B). OVA-specific IgG production was also examined using the sera collected from the mice described in Figure 5A . The level of OVA-specific IgG in the serum was notably decreased in mice injected (Figure 6A and B) . OVA-specific IgG production was also examined using the sera collected from the mice described in Figure 6A 
Discussion
Polymeric NPs prepared with PLGA have been intensely studied because of their clinically proven biocompatibility and safety. They are biodegradable and are completely hydrolyzed and removed from the body. 33 Polymeric NPs have been studied as a vehicle for delivering encapsulated antigens to phagocytes. [40] [41] [42] One of the major advantages of encapsulation is the prevention of degradation of the encapsulated antigen or drug in plasma. 43 Recent studies have also shown that PLGA-encapsulated antigen delivery to DCs enhances and prolongs the MHC-restricted presentation of the exogenous antigens. 42, 44 In the present study, PLGA-NPs containing both antigen and an immunosuppressive drug were produced and the induction of antigen-specific immune tolerance by the NPs was studied in mice as well as in vitro.
Our results show that NP[OVA+Dex]-treated DCs were defective in antigen-specific T cell stimulation, expression of MHC class II and co-stimulatory molecules (CD80 and CD86), and secretion of pro-inflammatory cytokines (IL-1β, IL-6, IL-12, and TNF-α). However, the production of (80 μg/mouse as OVA), or PBS. After 7 days, the sera were collected from the mice, and OVA-specific IgG levels were measured by ELISA. The data are presented as the mean ± SD of three independent experiments. *P<0.05, **P<0.01, ***P<0.001. "ns" indicates no significant difference. The average size of the NP[OVA+Dex] fabricated in the present study was 864.8 nm, a size that can be readily phagocytosed by professional APCs and large enough to contain sufficient amounts of antigen and drug. Previous studies have shown that polymeric NPs ranging in size from 300 nm to 2 micron are efficiently taken up by phagocytosis by professional APCs, although the maximum cellular uptake of NPs is dependent upon various factors such as particle size and surface charge. 38, 39, [46] [47] [48] Polymeric NPs with a size range <200 nm are not suitable for the preferential delivery of encapsulated antigen or drug to APCs, as they can escape phagocytic recognition with minimal uptake by endocytosis. 49, 50 One of the major findings of the present study is that NP 
Conclusion
The present study showed that DCs treated with NP[OVA +Dex] exhibited tolerogenic DC properties and OVAspecific as well as antigen-nonspecific immune suppression. Tolerogenic DCs generated by NP [OVA+Dex] efficiently induced the differentiation of naïve T cells into regulatory T cells. This study also demonstrated that intragastric feeding as well as intravenous injection of NP[OVA+Dex] induced OVA-specific immune tolerance in mice. The current findings indicate that polymeric NPs encapsulating both antigen and Dex can serve as a means of targeted delivery to phagocytes, thus reducing the potential side effects of Dex and enabling the generation of antigen-specific immune tolerance, which is crucial for the treatment of autoimmune diseases.
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Figure S2
In vitro release kinetics. NP [OVA+Dex] was incubated in buffers with pH 3.0 and pH 7.0 at 37°C. At indicated time points, the NP[OVA+Dex] was collected by centrifuging at 3,000g for 10 min, and then lysed in a lysis buffer containing 0.5% SDS and 0.5 N NaOH for the determination of OVA content, or in a 1:1 mixture of DMSO and methanol for the determination of Dex. The OVA content was determined using a microbicinchoninic acid assay, and the Dex content was determined using HPLC, as described in detail in the methods section.
